[4] NICE recommends that semaglutide (Wegovy) should be considered for adults with a BMI of 35 kg/m or more, or between 30 and 34.9 kg/m in the presence of at least one weight-related comorbidity, and who have tried standard care without achieving or maintaining adequate weight loss
Background Alcohol use disorder contributes significantly to the global disease burden, and although various psychosocial and pharmacological treatment options for AUD are available, they are often under-utilized
89Bio, which is developing pegozafermin, an investigational glycopegylated FGF21 analog for NASH, saw its stock fall about 16% to $8.21
Arch Neurol 64:954956 Martinez-Cruz F, Pozo D, Osuna C, Espinar A, Marchante C, Guerrero JM (2002) Oxidative stress induced by phenylketonuria in the rat: prevent by melatonin, vitamin E and vitamin C